The Netherlands ∙ Proposed Solutions to Tackle Expensive Medicines in The Netherlands: A Critical Review

If you have an interest in Life Sciences, I am glad to draw your attention to my Report in the latest edition of the European Pharmaceutical Law Review (EPLR). As many of you know, the cost of medicines is a frequent subject of debate in the Netherlands. In order to find solutions to this recurring issue, a report was published by the Council for Public Healthcare and Society (RVS), proposing compulsory patent licensing and the wider application of the compounding exemption (formula magistralis) as possible solutions. Please find my (critical) review here.


Navigate through our knowledgebase

Related articles

Article

A case of so-called fiscal neutrality

Sometimes you come across cases that violate Mandalorian Creed: “One does not speak unless one knows.”. This happened to me last week when I read the Dutch Supreme Court’s judgment in a…

Read more

Article

Can we fix / improve the MDR and the IVDR?

Or in other words that I’ve asked on this blog before: can the maker repair what he makes? This blog will argue that he can and he should. It still happens to…

Read more

Article

MDR and IVDR amendment has entered into force now

Today is the day that the amendment, aka the ‘extension’, to the MDR enters into force because it was published in the EU’s Official Journal today, number L080. As you are reading this,…

Read more